Advances in the application of nanoparticles for the diagnosis and treatment of diabetic cardiomyopathy
Frontiers in Cell and Developmental Biology · 21.08.2026 · 14
DOI: 10.3389/fcell.2026.1912847 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 21.08.2026. Verfasst von Jia Feng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, The Affiliated Hospital of Southwest Medical University, Luzhou, China. Die Arbeit nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
As a frequent and serious cardiovascular complication of diabetes mellitus, diabetic cardiomyopathy (DCM) typically presents with an asymptomatic onset during its initial phase, followed by gradual worsening over time. Currently, no universally accepted and effective DCM-specific targeted therapeutic strategy is available. Recently, nanotechnology has gained recognition as a viable strategy to address the shortcomings of traditional treatments, leveraging its size-dependent effects, large specific surface area, and ability to integrate multiple functions. This article presents a structured summary of recent developments regarding nanoparticle utilization for diagnostic and therapeutic purposes in DCM. First, from a functional perspective, we analyze the core advantages of nanoparticles in improving pharmacokinetic profiles, enhancing drug stability and bioavailability, facilitating targeted myocardial delivery, enabling pathological microenvironment-responsive release, and constructing theranostic platforms. Second, according to material type, we discuss the current research status and the operational mechanisms of different nanocarrier systems—including polymeric nanoparticles, liposomes, inorganic nanoparticles, and extracellular vesicles—in antifibrotic therapy, antioxidation intervention, regulation of energy metabolism, and early diagnostic assessment. Finally, based on current limitations and successful experience from other cardiovascular diseases we outline future directions, including biomimetic design, upgraded targeting strategies, diversified administration routes, safety evaluation, and combined applications with hydrogels or myocardial patches. Although nanotechnology has shown promising potential in animal models of DCM, clinical translation still requires continued breakthroughs in material innovation, quality control, and long-term safety validation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
- Metabolic Vascular Diseases Key Laboratory of Sichuan Province, Southwest Medical University, Luzhou, China.
- Sichuan Clinical Research Center for Nephropathy, Luzhou, China.
- Sichuan-Chongqing Joint Key Laboratory of Metabolic Vascular Diseases, Luzhou, China.
- Department of Cardiology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
- Department of Endocrinology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Zitieren
APA
Feng, J., Huang, Y., He, Y., Deng, C., Jiang, Z., Li, Q., Li, Y., Lan, X., & Xu, Y. (2026). Advances in the application of nanoparticles for the diagnosis and treatment of diabetic cardiomyopathy. Frontiers in Cell and Developmental Biology, 14. https://doi.org/10.3389/fcell.2026.1912847
Vancouver
Feng J, Huang Y, He Y, Deng C, Jiang Z, Li Q, et al. Advances in the application of nanoparticles for the diagnosis and treatment of diabetic cardiomyopathy. Frontiers in Cell and Developmental Biology. 2026;14. doi:10.3389/fcell.2026.1912847
BibTeX
@article{Feng2026,
author = {Feng, Jia and Huang, Yuqing and He, Yufeng and Deng, Chenhao and Jiang, Zongzhe and Li, Qifu and Li, Yu and Lan, Xiaorong and Xu, Yong},
title = {Advances in the application of nanoparticles for the diagnosis and treatment of diabetic cardiomyopathy},
journal = {Frontiers in Cell and Developmental Biology},
year = {2026},
volume = {14},
doi = {10.3389/fcell.2026.1912847}
}
EUVIMED